J V Melo

1.8k total citations
27 papers, 1.3k citations indexed

About

J V Melo is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, J V Melo has authored 27 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 17 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in J V Melo's work include Chronic Myeloid Leukemia Treatments (20 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Eosinophilic Disorders and Syndromes (11 papers). J V Melo is often cited by papers focused on Chronic Myeloid Leukemia Treatments (20 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Eosinophilic Disorders and Syndromes (11 papers). J V Melo collaborates with scholars based in United Kingdom, Australia and United States. J V Melo's co-authors include J M Goldman, Nicholas C.P. Cross, Feng Lin, Timothy P. Hughes, David M. Ross, David Barnes, Jane F. Apperley, Giovanna Lombardi, Kate Cwynarski and Francesco Dazzi and has published in prestigious journals such as Oncogene, International Journal of Cancer and Journal of Clinical Pathology.

In The Last Decade

J V Melo

27 papers receiving 1.3k citations

Peers

J V Melo
Kimberly Hayes United States
Gabriele Gugliotta Italy
Ton van Agthoven Netherlands
Margaret Nieborowska-Skorska United States
Rachel Okabe United States
S. Tiong Ong United States
Roger Luo United States
Wolfgang Warsch Austria
Sandra Moore United States
Sébastien Malinge United States
Kimberly Hayes United States
J V Melo
Citations per year, relative to J V Melo J V Melo (= 1×) peers Kimberly Hayes

Countries citing papers authored by J V Melo

Since Specialization
Citations

This map shows the geographic impact of J V Melo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J V Melo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J V Melo more than expected).

Fields of papers citing papers by J V Melo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J V Melo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J V Melo. The network helps show where J V Melo may publish in the future.

Co-authorship network of co-authors of J V Melo

This figure shows the co-authorship network connecting the top 25 collaborators of J V Melo. A scholar is included among the top collaborators of J V Melo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J V Melo. J V Melo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Casolari, Débora A., et al.. (2012). Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5. Leukemia. 27(2). 409–415. 22 indexed citations
2.
Ross, David M., Susan Branford, John F. Seymour, et al.. (2010). Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 24(10). 1719–1724. 194 indexed citations
3.
4.
Mancuso, Anthony, Thi Bui, Xiangmin Tong, et al.. (2010). Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprograming. Oncogene. 29(20). 2962–2972. 150 indexed citations
5.
Ross, David M., Timothy P. Hughes, & J V Melo. (2010). Do we have to kill the last CML cell?. Leukemia. 25(2). 193–200. 31 indexed citations
6.
Markova, Boyka, Corinna Albers, Frank Breitenbuecher, et al.. (2009). Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway. Oncogene. 29(5). 739–751. 49 indexed citations
7.
Bonhoure, Elisabeth, David Barnes, Bernard Malavaud, et al.. (2008). Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia. 22(5). 971–979. 86 indexed citations
8.
Chase, Andrew, Beate Schultheis, Sebastian Kreil, et al.. (2008). Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. Leukemia. 23(2). 358–364. 8 indexed citations
9.
Brazma, Diana, C. Grace, Julie Howard, et al.. (2007). Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes and Cancer. 46(11). 1039–1050. 39 indexed citations
10.
11.
Khorashad, Jamshid S., Mona Anand, David Marin, et al.. (2006). The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia. 20(4). 658–663. 119 indexed citations
12.
Radujkovic, Aleksandar, Julian Topaly, Marlon R. Veldwijk, et al.. (2005). Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG. Leukemia. 19(7). 1198–1206. 78 indexed citations
13.
Chuah, Charles, David Barnes, Marwan Kwok, et al.. (2005). Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia. 19(11). 1896–1904. 42 indexed citations
14.
Barnes, David, Darren R. Veach, W. G. BORNMANN, et al.. (2004). Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Leukemia. 18(8). 1352–1356. 33 indexed citations
15.
Melo, J V, et al.. (2001). Specific action of FGFR inhibitors against t(4;14) positive myeloma cells. ePrints Soton (University of Southampton). 1 indexed citations
16.
Melo, J V, et al.. (1995). Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia.. PubMed. 9(4). 734–9. 2 indexed citations
17.
Cross, Nicholas C.P., J V Melo, Feng Lin, & J M Goldman. (1994). An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.. PubMed. 8(1). 186–9. 204 indexed citations
18.
Zola, Heddy, et al.. (1990). The leukocyte-common antigen (CD45) complex and b-lymphocyte activation. Human Immunology. 27(4). 368–377. 29 indexed citations
19.
Th'ng, K. H., Robert E. Kearney, J V Melo, et al.. (1987). Establishment and characterization of three new malignant lymphoid cell lines. International Journal of Cancer. 39(1). 89–93. 23 indexed citations
20.
Brito-Babapulle, V, J V Melo, Letizia Foroni, et al.. (1984). Neoplastic x and λ cells in a B‐PLL with chromosome translocations of both light chain gene regions. International Journal of Cancer. 34(6). 769–773. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kimberly Hayes Breakdown of academic impact, for papers by Gabriele Gugliotta Breakdown of academic impact, for papers by Ton van Agthoven Breakdown of academic impact, for papers by Margaret Nieborowska-Skorska Breakdown of academic impact, for papers by Rachel Okabe Breakdown of academic impact, for papers by S. Tiong Ong Breakdown of academic impact, for papers by Roger Luo Breakdown of academic impact, for papers by Wolfgang Warsch Breakdown of academic impact, for papers by Sandra Moore Breakdown of academic impact, for papers by Sébastien Malinge
Rankless by CCL
2026